زائر
The ests VX-950 has psted s fa ae vey exiting," Aan Wsey, an anayst with Deisin eses, td nited Pess Intenatina.
"It's exiting t see that devepment f the ptease inhibits as a ass is advaning," Wsey added.
Sheing-Pgh's ptease inhibit SH-503034 as is in phase 2 devepment.
Wsey pjeted bth Vetex's and Sheing's dg wd ahieve peak yea saes f p t $1.2 biin.
Pdentia anayst Jasn Zhang pedited VX-950 wd beat the the ptease inhibits and beme the fist t get appved.
"We've nt yet ennteed any evidene t sggest that Vetex's dg shd nt eah the maket fist and ead t impessive saes," Zhang stated in a eseah ept eeased Wednesday.
He eiteated his "veweight" ating n the stk, stating, "VX-950 shd be n the fast tak t appva."
In additin t pesenting phase 2 data fm a 28-day stdy at the Week nfeene in s Angees, Vetex as annned that it was initiating tw additina phase 2 tias f VX-950.
In the 28-day stdy, whih invved VX-950 in mbinatin with pegyated-intefen and ibaviin, 12 f 12 patients ahieved pasma NA eves bew the imit f detetin at the end f teatment. Eeven f these patients ntined t have ndetetabe eves f the vis afte 12 additina weeks f teatment with pegyated-intefen and ibaviin.
"We think Vetex's thee-mnth mbinatin stategy has a stng ikeihd f ahieving signifianty highe (sstained via espnse) ates than the ent standad f ae with 48 weeks f teatment," Zhang stated. "We find yesteday's data as sppt sh a stategy," he added.
"In additin, bease f the seis txiities assiated with ng-se intefen , we beieve that eventa appva wi be ikey if VX-950 meey shws simia effiay with a shte datin f intefen theapy," Zhang said.
In additin, the HV ptease inhibits in devepment appea t be fa behind VX-950.
Intemne has a pste pesentatin abt its dg at the nfeene, bt this nsisted ny f peinia data.
"Whie the in vit and anima mdes pesented seemed pmising, we beieve that it is sti fa t eay t deem the dg as a signifiant theat t VX-950 at this time," Zhang stated.
He nted that "n data fm the HV ptease inhibit pgams wee pesented at the meeting, inding SH503034 and Bist-Myes's ppted ptease inhibit."
Vetex said the additina phase 2 tias wd hep answe qestins abt VX-950's effetiveness.
"We beieve the 2006 gba Phase II pgam wi estabish VX-950's inia pfie by answeing key qestins abt (sstained via espnse) ates, teatment datin and the e f ibaviin," said Jhn Aam, Vetex's exetive vie pesident f mediines devepment and hief media ffie.
Vetex said the tw phase 2 stdies -- PVE 1 and PVE 2 -- ae sated t stat in Jne. The mpany said it as expets t begin a phase 2b stdy in patients wh faied n standad f ae teatment in the send haf f the yea.
Zah Babe, Vetex spkesman, td PI the PVE 1 stdy, whih wi take pae in the nited States, has aeady been initiated and dsing wi begin in Jne. The PVE 2 stdy wi be initiated in Epe in Jne.
Babe said the fist inia data fm the phase 2 stdies wi ikey stat ming t at the end f the yea, with sstained via espnse data beming avaiabe in eay 2007.
Vetex pans t anh phase 3 tias in mid-2007 t be n tak t fie a new dg appiatin with the Fd and Dg Administatin in 2008, Babe added.
The pimay bjetive f PVE 1 and PVE 2 is t detemine the pptin f patients wh ahieve sstained via espnse, whih is defined as ndetetabe eves f the vis 24 weeks afte the mpetin f dsing. VX-950 wi be given in njntin with pegyated-intefen and ibaviin in diffeent stdy ams that invve 12 weeks, 24 weeks and 48 weeks f teatment.
Bank f Ameia anayst David Witzke pgaded the stk fm se t neta based n what he saw as psitive hanges in Vetex's phase 2 tias f VX-950.
"We beieve the new Phase II design wes isk by addessing imptant qestins eaie that wd thewise have been answeed in Ph III," Witzke wte in a eseah ept issed Wednesday. "This indes having a bette hane at detemining the ptima datin f theapy and whethe nt a 72 wk standad f ae nt am wi be neessay in Ph III."
نتمني ان تتم التجربة الثالثة بنجاح ليتم استخدام وتوزيع هذا العلاج الذي اثبت انه قادر علي
القضاء علي الفيرس خلال فتره قصيرة وهو عباره تنظيف الدم من الفيروس ليصبح الفيروس غير ضار.
شكرا. باحث باثيولوجي.
"It's exiting t see that devepment f the ptease inhibits as a ass is advaning," Wsey added.
Sheing-Pgh's ptease inhibit SH-503034 as is in phase 2 devepment.
Wsey pjeted bth Vetex's and Sheing's dg wd ahieve peak yea saes f p t $1.2 biin.
Pdentia anayst Jasn Zhang pedited VX-950 wd beat the the ptease inhibits and beme the fist t get appved.
"We've nt yet ennteed any evidene t sggest that Vetex's dg shd nt eah the maket fist and ead t impessive saes," Zhang stated in a eseah ept eeased Wednesday.
He eiteated his "veweight" ating n the stk, stating, "VX-950 shd be n the fast tak t appva."
In additin t pesenting phase 2 data fm a 28-day stdy at the Week nfeene in s Angees, Vetex as annned that it was initiating tw additina phase 2 tias f VX-950.
In the 28-day stdy, whih invved VX-950 in mbinatin with pegyated-intefen and ibaviin, 12 f 12 patients ahieved pasma NA eves bew the imit f detetin at the end f teatment. Eeven f these patients ntined t have ndetetabe eves f the vis afte 12 additina weeks f teatment with pegyated-intefen and ibaviin.
"We think Vetex's thee-mnth mbinatin stategy has a stng ikeihd f ahieving signifianty highe (sstained via espnse) ates than the ent standad f ae with 48 weeks f teatment," Zhang stated. "We find yesteday's data as sppt sh a stategy," he added.
"In additin, bease f the seis txiities assiated with ng-se intefen , we beieve that eventa appva wi be ikey if VX-950 meey shws simia effiay with a shte datin f intefen theapy," Zhang said.
In additin, the HV ptease inhibits in devepment appea t be fa behind VX-950.
Intemne has a pste pesentatin abt its dg at the nfeene, bt this nsisted ny f peinia data.
"Whie the in vit and anima mdes pesented seemed pmising, we beieve that it is sti fa t eay t deem the dg as a signifiant theat t VX-950 at this time," Zhang stated.
He nted that "n data fm the HV ptease inhibit pgams wee pesented at the meeting, inding SH503034 and Bist-Myes's ppted ptease inhibit."
Vetex said the additina phase 2 tias wd hep answe qestins abt VX-950's effetiveness.
"We beieve the 2006 gba Phase II pgam wi estabish VX-950's inia pfie by answeing key qestins abt (sstained via espnse) ates, teatment datin and the e f ibaviin," said Jhn Aam, Vetex's exetive vie pesident f mediines devepment and hief media ffie.
Vetex said the tw phase 2 stdies -- PVE 1 and PVE 2 -- ae sated t stat in Jne. The mpany said it as expets t begin a phase 2b stdy in patients wh faied n standad f ae teatment in the send haf f the yea.
Zah Babe, Vetex spkesman, td PI the PVE 1 stdy, whih wi take pae in the nited States, has aeady been initiated and dsing wi begin in Jne. The PVE 2 stdy wi be initiated in Epe in Jne.
Babe said the fist inia data fm the phase 2 stdies wi ikey stat ming t at the end f the yea, with sstained via espnse data beming avaiabe in eay 2007.
Vetex pans t anh phase 3 tias in mid-2007 t be n tak t fie a new dg appiatin with the Fd and Dg Administatin in 2008, Babe added.
The pimay bjetive f PVE 1 and PVE 2 is t detemine the pptin f patients wh ahieve sstained via espnse, whih is defined as ndetetabe eves f the vis 24 weeks afte the mpetin f dsing. VX-950 wi be given in njntin with pegyated-intefen and ibaviin in diffeent stdy ams that invve 12 weeks, 24 weeks and 48 weeks f teatment.
Bank f Ameia anayst David Witzke pgaded the stk fm se t neta based n what he saw as psitive hanges in Vetex's phase 2 tias f VX-950.
"We beieve the new Phase II design wes isk by addessing imptant qestins eaie that wd thewise have been answeed in Ph III," Witzke wte in a eseah ept issed Wednesday. "This indes having a bette hane at detemining the ptima datin f theapy and whethe nt a 72 wk standad f ae nt am wi be neessay in Ph III."
نتمني ان تتم التجربة الثالثة بنجاح ليتم استخدام وتوزيع هذا العلاج الذي اثبت انه قادر علي
القضاء علي الفيرس خلال فتره قصيرة وهو عباره تنظيف الدم من الفيروس ليصبح الفيروس غير ضار.
شكرا. باحث باثيولوجي.
التعديل الأخير بواسطة المشرف: